Aimmune Therapeutics (AIMT) Shares Up 6.1%

Aimmune Therapeutics Inc (NASDAQ:AIMT) shot up 6.1% during trading on Thursday . The company traded as high as $23.76 and last traded at $23.75. 997,369 shares traded hands during mid-day trading, an increase of 53% from the average session volume of 649,791 shares. The stock had previously closed at $22.39.

A number of research firms recently commented on AIMT. Cantor Fitzgerald reiterated an “overweight” rating on shares of Aimmune Therapeutics in a research report on Friday, November 23rd. BidaskClub downgraded Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday. Credit Suisse Group set a $40.00 target price on Aimmune Therapeutics and gave the stock a “buy” rating in a research report on Monday, November 19th. ValuEngine downgraded Aimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 12th. Finally, Wedbush set a $80.00 target price on Aimmune Therapeutics and gave the stock a “buy” rating in a research report on Monday, November 12th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $51.70.

The stock has a market cap of $1.31 billion, a PE ratio of -9.10 and a beta of -0.13.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.03. On average, equities analysts expect that Aimmune Therapeutics Inc will post -3.55 earnings per share for the current fiscal year.

In related news, insider Jayson Donald Alexander Dallas acquired 3,650 shares of the firm’s stock in a transaction on Monday, November 19th. The shares were acquired at an average cost of $27.56 per share, for a total transaction of $100,594.00. Following the completion of the transaction, the insider now directly owns 63,600 shares in the company, valued at approximately $1,752,816. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 24.56% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. Northern Trust Corp grew its stake in Aimmune Therapeutics by 26.3% in the second quarter. Northern Trust Corp now owns 518,581 shares of the biotechnology company’s stock worth $13,945,000 after purchasing an additional 108,034 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in Aimmune Therapeutics by 12.9% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 207,255 shares of the biotechnology company’s stock valued at $5,574,000 after acquiring an additional 23,678 shares in the last quarter. BlackRock Inc. boosted its position in Aimmune Therapeutics by 18.4% during the 2nd quarter. BlackRock Inc. now owns 3,643,840 shares of the biotechnology company’s stock valued at $97,984,000 after acquiring an additional 565,410 shares in the last quarter. Spark Investment Management LLC boosted its position in Aimmune Therapeutics by 22.7% during the 2nd quarter. Spark Investment Management LLC now owns 232,300 shares of the biotechnology company’s stock valued at $6,246,000 after acquiring an additional 43,000 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in Aimmune Therapeutics by 25.0% during the 2nd quarter. Rhumbline Advisers now owns 41,731 shares of the biotechnology company’s stock valued at $1,122,000 after acquiring an additional 8,348 shares in the last quarter. Hedge funds and other institutional investors own 75.04% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Aimmune Therapeutics (AIMT) Shares Up 6.1%” was published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://sportsperspectives.com/2018/12/07/aimmune-therapeutics-aimt-shares-up-6-1.html.

About Aimmune Therapeutics (NASDAQ:AIMT)

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.

Read More: Average Daily Trade Volume – What You Need to Know

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply